Towards personalized therapy for patients with glioblastoma

摘要: Combined therapy with temozolomide and radiotherapy is a standard treatment improves the survival for patients newly diagnosed glioblastoma. However, prognosis remains poor, median time of 12–15 months. Currently, several clinical trials dose-dense regimen or molecular-targeting therapies have been performed to overcome resistance In these therapies, rational prognostic biomarkers also investigated predict their outcome response treatment. This advanced understanding biological markers can help develop personalized glioblastoma patients. Generally, due reduced tolerance, elderly do not seem benefit from intensive population needs individual treatments depended on age performance status. this article, we review recent studies that provide glioblastoma, based molecular tumor profiling patients’ physical